Article
CYP17A1 polymorphism c.-362T>C predicts clinical outcome in metastatic castration-resistance prostate cancer patients treated with abiraterone.
Cancer chemotherapy and pharmacology - 1 Oct 2020
Crucitta Stefania, Del Re Marzia, Paolieri Federico, Bloise Francesco, Sbrana Andrea, Sammarco Enrico, Mercinelli Chiara, Cucchiara Federico, Fontanelli Lorenzo, Galli Luca, Danesi Romano
Abstract excerpt
BACKGROUND: Abiraterone became a standard hormonal therapy for patients with metastatic castration-resistance prostate cancer (mCRPC). However, patients may experience primary resistance to treatment. To date, few predictive biomarkers of efficacy have been identified. Our aim was to investigate the association between the single nucleotide polymorphism (SNP) c.-362T>C in the CYP17A1 gene, and clinical outcome in...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.